Fresh analysis reveals that patients who stop using new GLP-1 drugs like semaglutide or tirzepatide may regain reduced body mass much more quickly than those who halt conventional lifestyle plans.
Research printed in a prominent health publication shows that while obese people frequently drop about a fifth of their total mass while undergoing treatment, the weight returns at an average rate of 0.8 kg per month upon discontinuation.
"People using such medications should be aware of the danger of quick rebound weight gain when the treatment ends," stated expert Dr. Susan Jebb.
Such speed of regain implies a reversion to starting mass in about a year and a half.
Analyzing Treatments
The research, which reviewed 37 of trials involving over 9,000 of participants, compared the outcomes of the injectable medications with other pills.
Scientists point out that individuals who lose weight through lifestyle changes alone generally see a less rapid weight regain—perhaps 0.1 kg a month—post-intervention.
Explaining the Rapid Regain
Doctors suggest the way of the injections accounts for the heightened regain.
These medications imitate a body's own chemical called GLP-1, which moderates appetite.
"Long-term administration of GLP-1 levels several times higher than normal may cause the system to produce less of its endogenous hormone, and may also diminish sensitivity to its effects," said Dr. Adam Collins, a dietetics specialist.
"Withdrawal of this GLP-1 'fix' results in hunger is uncontrolled, making overeating much more probable."
An Ongoing Disease?
Health authorities advise the jabs for individuals with obesity-related health risks, accompanied by recommended diet and exercise modifications.
A number of clinicians say that, considering the significant potential of weight regain, the treatment should be considered long-term.
This perspective is reinforced by drug manufacturers, who note that the findings "highlight the chronic character of excess weight," similar to managing diseases like high blood pressure.
Patient Accounts
Users who have stopped the jabs report a sudden return of hunger.
"It was like something activating and you're instantly ravenous," described a patient.
The struggle is compounded if patients have not established lasting lifestyle or habit modifications during therapy.
Growing Use
Figures indicate that millions of people in the UK have used these injections in the past year, with desire continuing to grow.
- Adoption is higher among females than men.
- The 40s and 50s demographic shows the greatest usage rates.
- Many obtain the medications through private healthcare rather than public health services.
Ultimately, researchers emphasize that while GLP-1 drugs are powerful tools for shedding pounds, they are not a magic cure and maintained weight loss hinges on ongoing behavioural management.
